Arul M. Chinnaiyan

Arul M. Chinnaiyan

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Arul M. Chinnaiyan

Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in Neoplasia
Verified
Journal Article
Open access
DRDaniel R. Rhodes
Daniel R. Rhodes
JYJianjun Yu
Jianjun Yu
KSK. Shanker
K. Shanker
NDNandan Deshpande
Nandan Deshpande
RVRadhika Varambally
Radhika Varambally
ACArul M. Chinnaiyan
Arul M. Chinnaiyan
DNA microarray technology has led to an explosion of oncogenomic analyses, generating a wealth of data and uncovering the complex gene expression patterns of cancer. Unfortunately, due to the lack of a unifying bioinformatic resource, the majority of these data sit stagnant and disjointed following publication, massively underutilized by the cancer research community. Here, we present ONCOMINE, a cancer microarray database and web-based data-mining platform aimed at facilitating discovery from genome-wide expression analyses. To date, ONCOMINE contains 65 gene expression datasets comprising nearly 48 million gene expression measurements form over 4700 microarray experiments. Differential expression analyses comparing most major types of cancer with respective normal tissues as well as a variety of cancer subtypes and clinical-based and pathology-based analyses are available for exploration. Data can be queried and visualized for a selected gene across all analyses or for multiple genes in a selected analysis. Furthermore, gene sets can be limited to clinically important annotations including secreted, kinase, membrane, and known gene-drug target pairs to facilitate the discovery of novel biomarkers and therapeutic targets.

1 May 2015 in Cell
Verified
Journal Article
Closed access
DRDan Robinson
Dan Robinson
EAEliezer M. Van Allen
Eliezer M. Van Allen
YWYi-Mi Wu
Yi-Mi Wu
NSNikolaus Schultz
Nikolaus Schultz
RLRobert J. Lonigro
Robert J. Lonigro
ACArul M. Chinnaiyan
Arul M. Chinnaiyan

19 January 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MIMatthew K Iyer
Matthew K Iyer
YNYashar S Niknafs
Yashar S Niknafs
RMRohit Malik
Rohit Malik
USUdit Singhal
Udit Singhal
ASAnirban Sahu
Anirban Sahu
ACArul M Chinnaiyan
Arul M Chinnaiyan

20 May 2012 in Nature
Verified
Journal Article
Open access
PDF file
CGCatherine S. Grasso
Catherine S. Grasso
YWYi-Mi Wu
Yi-Mi Wu
DRDan R. Robinson
Dan R. Robinson
XCXuhong Cao
Xuhong Cao
SDSaravana M. Dhanasekaran
Saravana M. Dhanasekaran
STScott A. Tomlins
Scott A. Tomlins
Exome sequencing is used to investigate the role of mutations and copy number aberrations in metastatic castration-resistant prostate cancer, revealing recurrent mutations in multiple chromatin/histone modifying genes, as well as genes involved in androgen signalling. Great strides have been made in the treatment of localized prostate cancer, but the metastatic disease and its progression to castration-resistant prostate cancer (CRPC) are commonly lethal. This study uses whole-exome sequencing of 132 samples comprising tumour and matched germ line from 50 patients with heavily treated CRPC, and 11 untreated high-grade localized prostate cancers. Although the overall mutation rate is low, the authors find recurrent mutations in multiple chromatin/histone-modifying genes, as well as in the gene encoding the androgen receptor. They identify a diverse series of potentially driving mutations and copy-number alterations in both known and novel genes and pathways, including FOXA1. Characterization of the prostate cancer transcriptome and genome has identified chromosomal rearrangements and copy number gains and losses, including ETS gene family fusions, PTEN loss and androgen receptor (AR) amplification, which drive prostate cancer development and progression to lethal, metastatic castration-resistant prostate cancer (CRPC)1. However, less is known about the role of mutations2,3,4. Here we sequenced the exomes of 50 lethal, heavily pre-treated metastatic CRPCs obtained at rapid autopsy (including three different foci from the same patient) and 11 treatment-naive, high-grade localized prostate cancers. We identified low overall mutation rates even in heavily treated CRPCs (2.00 per megabase) and confirmed the monoclonal origin of lethal CRPC. Integrating exome copy number analysis identified disruptions of CHD1 that define a subtype of ETS gene family fusion-negative prostate cancer. Similarly, we demonstrate that ETS2, which is deleted in approximately one-third of CRPCs (commonly through TMPRSS2:ERG fusions), is also deregulated through mutation. Furthermore, we identified recurrent mutations in multiple chromatin- and histone-modifying genes, including MLL2 (mutated in 8.6% of prostate cancers), and demonstrate interaction of the MLL complex with the AR, which is required for AR-mediated signalling. We also identified novel recurrent mutations in the AR collaborating factor FOXA1, which is mutated in 5 of 147 (3.4%) prostate cancers (both untreated localized prostate cancer and CRPC), and showed that mutated FOXA1 represses androgen signalling and increases tumour growth. Proteins that physically interact with the AR, such as the ERG gene fusion product, FOXA1, MLL2, UTX (also known as KDM6A) and ASXL1 were found to be mutated in CRPC. In summary, we describe the mutational landscape of a heavily treated metastatic cancer, identify novel mechanisms of AR signalling deregulated in prostate cancer, and prioritize candidates for future study.

1 February 2009 in Nature
Verified
Journal Article
Closed access
ASArun Sreekumar
Arun Sreekumar
LPLaila M. Poisson
Laila M. Poisson
TRThekkelnaycke M. Rajendiran
Thekkelnaycke M. Rajendiran
AKAmjad P. Khan
Amjad P. Khan
QCQi Cao
Qi Cao
ACArul M. Chinnaiyan
Arul M. Chinnaiyan

1 February 2007 in Neoplasia
Verified
Journal Article
Open access
DRDaniel R. Rhodes
Daniel R. Rhodes
SKShanker Kalyana-Sundaram
Shanker Kalyana-Sundaram
VMVasudeva Mahavisno
Vasudeva Mahavisno
RVRadhika Varambally
Radhika Varambally
JYJianjun Yu
Jianjun Yu
ACArul M. Chinnaiyan
Arul M. Chinnaiyan
DNA microarrays have been widely applied to cancer transcriptome analysis; however, the majority of such data are not easily accessible or comparable. Furthermore, several important analytic approaches have been applied to microarray analysis; however, their application is often limited. To overcome these limitations, we have developed Oncomine, a bioinformatics initiative aimed at collecting, standardizing, analyzing, and delivering cancer transcriptome data to the biomedical research community. Our analysis has identified the genes, pathways, and networks deregulated across 18,000 cancer gene expression microarrays, spanning the majority of cancer types and subtypes. Here, we provide an update on the initiative, describe the database and analysis modules, and highlight several notable observations. Results from this comprehensive analysis are available at http://www.oncomine.org.